Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.

Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR.

AIDS. 2009 Jun 1;23(9):1035-46. doi: 10.1097/QAD.0b013e32832ba8ec. Review.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.

Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB; Terry Beirn Community Programs for Clinical Research on AIDS and the International Network for Strategic Initiatives in Global HIV Trials.

AIDS. 2010 Jan 28;24(3):395-403.

4.

Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.

Katusiime C, Ocama P, Kambugu A.

Afr Health Sci. 2014 Sep;14(3):679-81. doi: 10.4314/ahs.v14i3.25. Review.

5.

Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, Laborde-Balen G, Aghokeng A, Suzan-Monti M, Delaporte E, Spire B, Carrieri MP, Laurent C; Stratall ANRS 12110/ESTHER Study Group.

HIV Med. 2014 Sep;15(8):478-87. doi: 10.1111/hiv.12140. Epub 2014 Mar 3.

6.

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG.

AIDS. 2006 Jan 9;20(2):223-31.

PMID:
16511415
7.

Preventing and managing antiretroviral drug resistance.

Kuritzkes DR.

AIDS Patient Care STDS. 2004 May;18(5):259-73. Review.

PMID:
15186710
8.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
9.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
10.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

11.

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Al Hajjar SH, Frayha H, Althawadi S.

Ann Saudi Med. 2012 Nov-Dec;32(6):565-9. doi: 10.5144/0256-4947.2012.565.

12.

[A problem of the HIV drug resistance].

Nosik MN.

Vopr Virusol. 2014 Jul-Aug;59(4):5-9. Review. Russian.

PMID:
25549461
13.

Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):356-64. doi: 10.1097/QAI.0b013e3182084b5a.

14.

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.

Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA.

Pharmacol Rev. 2012 Jul;64(3):803-33. doi: 10.1124/pr.111.005553. Review.

15.

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, Carpenter S, Giddy J, Ross D, Holst H, Losina E, Walker BD, Kuritzkes DR; South Africa Resistance Cohort Study Team.

Clin Infect Dis. 2008 May 15;46(10):1589-97. doi: 10.1086/587109.

16.

Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.

Gardner EM, Melendez AG, Astiz M, Bray K.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb;11(1):34-9. doi: 10.1177/1545109711422124. Epub 2011 Oct 4.

PMID:
21972263
17.

Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.

Gordon LL, Gharibian D, Chong K, Chun H.

AIDS Patient Care STDS. 2015 Jul;29(7):384-8. doi: 10.1089/apc.2014.0165. Epub 2015 Jun 4.

PMID:
26114665
18.

Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.

Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, Günthard HF, Cavassini M.

Clin Infect Dis. 2009 Jan 15;48(2):239-47. doi: 10.1086/595703.

19.

HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients.

Xing H, Ruan Y, Li J, Shang H, Zhong P, Wang X, Liao L, Li H, Zhang M, Xue Y, Wang Z, Su B, Liu W, Dong Y, Ma Y, Li H, Qin G, Chen L, Pan X, Chen X, Peng G, Fu J, Chen RY, Kang L, Shao Y; Chinese National HIVDR Surveillance and Monitoring Network.

PLoS One. 2013;8(2):e54917. doi: 10.1371/journal.pone.0054917. Epub 2013 Feb 6.

20.

Levels of adherence required for virologic suppression among newer antiretroviral medications.

Kobin AB, Sheth NU.

Ann Pharmacother. 2011 Mar;45(3):372-9. doi: 10.1345/aph.1P587. Epub 2011 Mar 8. Review.

PMID:
21386024

Supplemental Content

Support Center